Abstract
Hydroxyurea (HU) is frequently given as treatment for myelofibrosis (MF), but data on its efficacy and tolerability are scarce. The results of HU therapy were evaluated in 40 patients with hyperproliferative manifestations of primary (n = 32), post-polycythemia vera (n = 6), or post-essential thrombocythemia (n = 2) myelofibrosis. Median interval between diagnosis and HU start was 6.2 months (range 0–141.7). Reasons for treatment were constitutional symptoms (55%), symptomatic splenomegaly (45%), thrombocytosis (40%), leukocytosis (28%), pruritus (10%), and bone pain (8%). The starting dose was 500 mg/day, subsequently adjusted to the individual efficacy and tolerability. Response was bone pain 100%, constitutional symptoms 82%, pruritus 50%, splenomegaly 40%, and anemia 12.5%. According to the International Working Group for Myelofibrosis Research and Treatment criteria, clinical improvement was achieved in 16 patients (40%). Median duration of response was 13.2 months (range 3–126.2). Worsening of the anemia or appearance of pancytopenia were observed in 18 patients, requiring administration of erythropoietin-stimulating agents (n = 17) and/or danazol (n = 9). Oral or leg ulcers appeared in five patients and one had gastrointestinal symptoms. HU is an effective and generally well-tolerated therapy for the hyperproliferative manifestations of MF. The accentuation of the anemia often induced by HU is usually manageable with concomitant treatment.
Similar content being viewed by others
References
Jacobson RJ, Salo A, Fialkow PJ (1978) Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189–194
Barosi G (1999) Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17:2954–2970
Mesa RA, Verstovsek S, Cervantes F et al (2007) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 31:737–40
Kralowics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–90
Pardanani AD, Levine RL, Lasho T et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108:3472–76
Cervantes F (2005) Modern management of myelofibrosis. Br J Haematol 128:583–592
Guardiola P, Anderson JE, Bandini G et al (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societé Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93:2831–2838
Kröger N, Holler E, Kobbe G et al (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114:5264–70
Löfvenberg E, Wahlin A (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41:375–381
Manoharan A (1991) Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 77:252–254
Santos FP, Kantarjian HM, Jain N et al (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115:1131–36
Pardanani A, Hood H, Lasho T et al (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2 V617F and MPL W515L/K mutations. Leukemia 21:1658–68
Verstovsek S, Kantarjian HM, Pardanani AD et al (2008) The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ET-MF). Blood 112:1762, abstract
Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092–1097
Barosi G, Bordessoule D, Brière J et al (2005) Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 106:2849–2853
Tefferi A, Barosi G, Mesa R et al (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, from the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108:1497–503
Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC et al (2004) Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 127:399–403
Cervantes Alvarez-Larrán A, Hernández-Boluda JC et al (2006) Efficacy and safety of darbepoetin-alpha in the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 134:184–186
Cervantes F (2005) Alvarez Larrán A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 129:771–5
Brubaker LH, Brière J, Laszlo J et al (1982) Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med 142:1533–1537
Mesa RA, Steensma DP, Pardanani A et al (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101:2534–2541
Tefferi A, Cortes J, Verstovsek S et al (2006) Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108:1158–64
Tefferi A, Verstovsek S, Barosi G et al (2009) Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 27:4563–69
Oishi N, Swisher SN, Troup SB (1960) Busulfan therapy in myeloid metaplasia. Blood 15:863–872
Petti MC, Latagliata R, Spadea T et al (2002) Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 116:576–581
Bachleitner-Hofmann T, Gisslinger H (1999) The role of interferon-α in the treatment of idiopathic myelofibrosis. Ann Hematol 78:533–538
Tefferi A, Mesa RA, Nagomey DN, Schroeder G, Silverstein MN (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95:2226–2233
Elliott MA, Chen MG, Silverstein MN, Tefferi A (1998) Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 103:505–511
Löfvenberg E, Wahlin A, Roos G, Öst A (1990) Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 44:33–38
Acknowledgments
This work has been supported in part by the grant RD06/0020/0004 from the RETICS, Spanish Ministry of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Martínez-Trillos, A., Gaya, A., Maffioli, M. et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 89, 1233–1237 (2010). https://doi.org/10.1007/s00277-010-1019-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-010-1019-9